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Cyclooxygenase type-2 (COX-2) is overexpressed in malignant tumours including breast cancers, though the mechanism of
upregulation is unclear. This study aimed to determine COX-2 expression in ductal carcinoma in situ (DCIS) in comparison to
invasive breast cancer (IBC) and normal breast, and also to investigate the relationship of COX-2 expression with HER-2 expression,
oestrogen receptor (ER), tumour grade and cellular proliferation (Ki67) in DCIS. Cyclooxygenase type-2, HER-2, ER and Ki67
expression were determined by immunohistochemistry on paraffin tissue sections of DCIS (n¼187), IBC (n¼65) and normal breast
reduction tissue (n¼60). Cyclooxygenase type-2 expression in DCIS (67%, Po0.001) and IBC (63%, Po0.001) was significantly
greater than in normal breast (23%). There was no difference in COX-2 expression level between DCIS and IBC (P¼0.87) or
between normal breast from reduction mammoplasty tissue and normal breast ducts around DCIS (22%, P¼0.29). In DCIS, COX-2
expression was associated with higher cellular proliferation rates (Po0.0001), nuclear grade (P¼0.003), with ER negativity
(P¼0.003) and with HER-2 positivity (Po0.0001). Cyclooxygenase type-2 expression is upregulated in in situ breast cancer and is
associated with surrogate markers of an aggressive DCIS phenotype including nonoestrogen-regulated signalling pathways.
Cyclooxygenase type-2 inhibition may potentially prevent the development of ER-positive and ER-negative breast cancers.
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Cyclooxygenase type-2 (COX-2) is overexpressed in many human
malignant tumours (Sano et al, 1995; Wolff et al, 1998; Mohammed
et al, 1999; Tucker et al, 1999; Soslow et al, 2000) and has been
linked to the process of carcinogenesis (Liu et al, 2001), tumour
survival (Tsujii et al, 1998), invasion (Tsujii et al, 1997) and
metastasis (Tsujii and DuBois, 1995; Costa et al, 2002). Epidemio-
logical studies have reported a significant reduction in the
incidence of human gastro-intestinal cancers with COX inhibition
by NSAIDS (Shaheen et al, 2002). Although the evidence for breast
cancer prevention is less strong, a recent meta-analysis of 14
studies (six cohort, eight case-controlled) gave a combined
estimate of a reduced relative risk of 0.82 (95% confidence interval
0.75–0.89) with regular NSAID use (Khuder and Mutgi, 2001), but
this provided no data on the dose–response effect for NSAID type
or duration of use.
Pharmacological studies with selective COX-2 inhibitors in
animal models of breast cancer (and other cancers) have
consistently demonstrated a dose-dependent arrest of tumour
growth, invasion and metastasis (Alshafie et al, 2000; Harris et al,
2000; Rozic et al, 2001; Kundu and Fulton, 2002). These
epidemiological and animal data indicate the potential of long-
term COX-2 inhibition by the safer new generation of COX-2-
specific NSAIDS for breast cancer chemoprevention.
Early studies of COX-2 RNA/protein expression in invasive
breast cancer (IBC) yielded inconsistent findings, with expression
reported to be between 0 and 100% of samples (Parrett et al, 1997;
Hwang et al, 1998). Immunohistochemical studies of COX-2
antigen expression in IBC have produced more consistent findings,
with moderate or strong levels of COX-2 expression found in 36–
56% of IBCs (Soslow et al, 2000; Half et al, 2002; Ristimaki et al,
2002; Denkert et al, 2003; Spizzo et al, 2003; Watanabe et al, 2003),
with COX-2 expression predicting poorer disease-free survival
(Ristimaki et al, 2002; Denkert et al, 2003; Spizzo et al, 2003).
COX-2 upregulation appears to occur early in the process of
carcinogenesis, with overexpression reported in a number of
premalignant lesions and in in situ neoplasia of nonbreast
glandular epithelium (Eberhart et al, 1994; Kirschenbaum et al,
2000; Shirahama, 2000; Morris et al, 2001). To date, there are few
reports of COX-2 expression in ductal carcinoma in situ (DCIS) of
the breast. These have been limited to DCIS surrounding invasive
cancer (Soslow et al, 2000; Half et al, 2002), with only two studies
in primary DCIS (Shim et al, 2003; Watanabe et al, 2003). All these
studies have looked at less than 50 DCIS tumours, and have shown
moderate or strong COX-2 antigen expression in 60–85% of
lesions. Shim et al (2003) reported a correlation of COX-2
expression and nuclear grade in pure DCIS, although the study
lacked power to demonstrate an association with other markers
(Shim et al, 2003). No single study has yet specifically determined
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yCOX-2 expression in pure DCIS compared to invasive cancer and
normal breast epithelium (from breast reduction tissue) and the
relationship to surrogate molecular markers of pathways driving
cell proliferation in DCIS.
Despite the data on elevated COX-2 expression in breast
neoplasia, the mechanism of upregulation remains unclear. In
this study, we evaluated COX-2 expression in DCIS using
immunohistochemistry in comparison to expression in invasive
cancer and normal breast, and investigated the association
between COX-2 expression and cellular proliferation, nuclear
grade and HER-2 antigen expression in DCIS, since HER-2 is
overexpressed in at least two-thirds of in situ breast cancer (Allred
et al, 1993; Bobrow et al, 1995; Suo et al, 2001).
PATIENTS AND METHODS
Tissue specimens and selection
A retrospective study was performed on archival paraffin-
embedded formalin-fixed tissue samples of normal breast (reduc-
tion mammoplasty, n¼60), DCIS (n¼187) and IBC (n¼65) from
women who had undergone surgery at the University Hospital of
South Manchester. Antigen expression was assessed by immuno-
histochemistry. Samples were deliberately selected to include a
higher proportion of HER-2-positive invasive cancer and a lower
proportion of HER-2-negative DCIS than expected by random
selection, to compare COX-2 expression in HER-2-expressing/
nonexpressing tumours.
Immunohistochemistry (Figure 3)
An immunohistochemical assay of COX-2, Ki67, oestrogen
receptor (ER) and HER-2 was performed on paraffin wax sections
(3–5mm thick) of each tissue were mounted on APES (3-
aminopropyltriethoxysilane, Sigma) coated slides, de-waxed in
xylene and rehydrated prior to immunohistochemical staining.
Established protocols developed at the clinical research laboratory,
Paterson Institute for Cancer Research, Manchester (a UK
reference laboratory for HER-2 immunohistochemical staining)
were followed for each antigen (except COX-2); these have been
shown to produce reproducible immunostaining in DCIS (Gandhi
et al, 2000; Dowsett et al, 2001). For all molecular markers, antigen
retrieval was achieved by the pressure cooking method for 4min in
citrate buffer (pH¼6.0).
For COX-2 expression, a primary goat polyclonal anti-human
COX-2 antibody was used (sc-1745; Santa Cruz Biotechnology,
USA) as described in other studies assessing COX-2 expression by
immunohistochemistry (Komhoff et al, 2000; Shirahama, 2000;
Cianchi et al, 2001; Sales et al, 2001; Shirahama et al, 2001; Hasturk
et al, 2002; Muller-Decker et al, 2002) at a dilution of 1:100 for 1h,
followed by a biotinylated rabbit anti-goat secondary antibody
(DAKO, Z259) diluted 1:200 for 40min. Cyclooxygenase type-2
immunoreactivity was confirmed with another COX-2 primary
antibody (Cayman Chemical Company, Ann Arbor, MI, USA,
160112) in 50 DCIS sections. For Ki67 (MIB-1), a primary mouse
monoclonal antibody to MIB-1 was used (DAKO Ltd, UK, M7240)
at 1:50 for 1h, followed by a biotinylated goat anti-mouse
secondary antibody (DAKO Ltd, UK, E432) diluted 1:200 for
40min. For ER, a primary mouse anti-human ER antibody was
used (DAKO Ltd, UK, M7047), at 1:33 for 1h, followed by a
biotinylated secondary goat anti-mouse antibody (DAKO Ltd, UK,
E432), at 1:200 for 40min. For HER-2 labelling, a primary mouse
anti-human HER-2 antibody was used (DAKO Ltd, UK, A485) at
1:40 for 1h, followed by a biotinylated secondary rabbit anti-
mouse antibody (DAKO Ltd, UK, E413), at a 1:200 for 40min.
Antigen visualisation was achieved by applying a standard
streptavidin–biotin complex (ABC, Vector labs, UK, PK-6100)
for 30min followed by diaminobenzidene chromogen (DAB,
DAKO, UK) in 0.1% H2O2 PBS solution. Sections were counter-
stained with Gill’s haematoxylin.
A positive and negative control slide was included in each
immunohistochemical assay. The positive controls used were as
follows: COX-2 expression: high-grade transitional carcinoma of
the urinary bladder and skin (Mohammed et al, 1999; Komhoff
et al, 2000; Ristimaki et al, 2001); HER-2 expression: strongly HER-
2-positive (3þ) IBC; ER, PR and Ki67 expression: DCIS known to
express the appropriate antigen as determined in previous studies
of DCIS in our department. For negative controls, the appropriate
primary antibody was omitted and either PBS or an iso-type
matched IgG serum was applied. A specific COX-2 blocking
peptide (Cayman Chemical Company, Ann Arbor, MI, USA,
360107) was used as a negative control in 50 DCIS sections
stained with the Cayman anti-COX-2 antibody (160112) as
previously described (Half et al, 2002).
Evaluation of immunostaining
Immunostaining was evaluated by light microscopy blindly and
independently by GPB and ISB, and a consensus agreement was
achieved. Cyclooxygenase type-2 expression was scored 0 (absent),
1þ (weak), 2þ (moderate) and 3þ (strong) based on the extent
and intensity of epithelial cell staining (Half et al, 2002; Ristimaki
et al, 2002; Shim et al, 2003). Cyclooxygenase type-2 positivity was
defined as a score X2 (Shamma et al, 2000; Ristimaki et al, 2002;
Shim et al, 2003). HER-2 staining was scored 0 (absent) to 3
(maximum cyto-membranous staining seen, comparable to a 3þ
positive invasive cancer control), with a score X2 considered
HER-2 positive (Birner et al, 2001). Ki67 and ER scores were
calculated as the percentage of positively stained nuclei. Oestrogen
receptor positivity was defined as X5% stained nuclei, and has
been used in previous studies in DCIS in our unit (Holland et al,
1997; Gandhi et al, 1998, 2000; Boland et al, 2003b). For each
section, a minimum of 1000 cells were scored across randomly
selected areas of DCIS at a magnification of  400 using a grid
graticule and cell counter.
Statistical analysis
Cyclooxygenase type-2 expression scores between different breast
tissues were compared using the Mann–Whitney test. The
relationship between categorical variables was analysed using the
w
2 test and the association of categorical variables with continuous
variables analysed using the Kruskal–Wallis and Mann–Whitney
tests. Significance tests were two-tailed and a significance level of
5% was used throughout.
RESULTS
COX-2 immunostaining in different breast tissues
Cyclooxygenase type-2 immunostaining was determined in 372
samples of normal and neoplastic breast ductal epithelium (Table 1,
Figure 1). In all cases, positive cellular immunostaining was
cytoplasmic. Strong immunoreactivity was also observed in the
smooth muscle of the tunica media of blood vessels and in the
myoepithelial cells surrounding neoplastic breast ducts. No
immunoreactivity was seen in stromal cells or in vasculature
around normal breast ductules.
Cyclooxygenase type-2 expression in pure DCIS (n¼187) and
IBC (n¼65) was significantly higher than in normal breast tissue
(either from breast reduction tissue, n¼60 or from ducts
surrounding DCIS, n¼60, Po0.0001, Mann–Whitney test). There
was, however, no difference in the median COX-2 expression
between in situ and invasive cancer (P¼0.59), or between normal
tissue from breast reduction samples and normal ducts around
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score X2þ) for DCIS, invasive cancer and normal breast from
reduction and around DCIS was 67, 63, 23 and 22, respectively.
Comparable COX-2 Immunoreactivity was confirmed in DCIS with
a different COX-2 primary antibody from the Cayman Chemical
Company (Ann Arbor, MI, USA, 160112) in 50 DCIS sections.
C0X-2 expression in DCIS and other clinico-pathological
parameters
In DCIS, there was no association between COX-2 expression and
patient age above and below the age of 50 years (P¼0.34, Table 2).
Cyclooxygenase type-2 expression increased significantly with
increasing nuclear grade (P¼0.003), with the largest difference
Table 1 COX-2 expression in normal and neoplastic breast
COX-2 score (0¼absent to 3¼maximum)
Tissue No. 0 1 2 3 No. COX-2 +ve (score X2+) P-value
b
NB 60 25 (42%) 21 (35%) 12 (20%) 2 (3%) 14/60 (23%) Reference
NB around DCIS 60 33 (55%) 14 (23%) 9 (15%) 4 (7%) 13/60 (22%) 0.29
DCIS
Low
a 27 4 (15%) 11 (41%) 6 (22%) 6 (22%) 12/27 (44%)
Intermediate
a 64 8 (13%) 15 (23%) 27 (42%) 14 (22%) 41/64 (64%)
High
a 96 8 (8.3%) 16 (17%) 37 (39%) 35 (36%) 72/96 (75%)
Total 187 20 (11%) 42 (23%) 70 (37%) 55 (29%) 125/187 (67%) o0.0001
Invasive cancer
Grade 1 17 2 (12%) 6 (35%) 2 (15%) 7 (41%) 9/17 (53%)
Grade 2 17 1 (6%) 6 (35%) 6 (35%) 4 (45%) 10/17 (58%)
Grade 3 31 3 (10%) 6 (19%) 8 (26%) 14 (45% 22/31 (71%)
Total 65 6 (9%) 18 (28%) 16 (25%) 25 (39%) 41/65 (63%) o0.0001
NB was from breast reduction tissue and ducts surrounding DCIS. Cyclooxygenase type-2 expression was scored 0 (absent) to 3 (maximum intensity seen) on tissue sections
from each patient, with a score X2 considered COX-2 expression positive. The P-values (Mann–Whitney test) are for comparison to COX-2 expression in NB from breast
reduction tissue (Referent). COX-2¼cyclooxygenase type-2; NB¼normal breast; DCIS¼ductal carcinoma in situ.
aDCIS nuclear grade.
bMann–Whitney test.
*P < 0.0001
*P < 0.0001
*P < 0.0001
*P < 0.0001
*P = 0.59
*P = 0.29
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Figure 1 COX-2 expression in normal and neoplastic breast tissue. For
each tissue, the thick black horizontal bars represent the median COX-2
score, the boxes represent the interquartile range and the T-bars the full
range. The median COX-2 expression in neoplastic DCIS and invasive
cancer epithelium are significantly greater than in normal breast ducts
(Po0.0001), although there was no difference between DCIS and invasive
cancer in median expression (P¼0.59).
Table 2 COX-2 expression and clinicopathological parameters in
women with DCIS (n¼187) and IBC (n¼65)
Parameter Number % COX-2 +ve P-value
a
DCIS
Age (years)
o50 35 62% 0.34
X50 152 69%
Nuclear grade
Low 27 44%
Intermediate 64 64% 0.003
High 96 75%
ER status
Positive 111 58% 0.003
Negative 75 80%
Ki67 cell proliferation
o10% 93 55% o0.0001
X10% 90 79%
HER-2 status
Positive 102 82% o0.0001
Negative 85 48%
Invasive cancer
Age (years)
o50 23 64% 0.67
X50 42 62%
Nuclear grade
I 17 53%
II 17 58% 0.43
III 21 71%
ER status
Positive 40 50% 0.005
Negative 25 84%
Ki67 cell proliferation
o10% 29 50% 0.04
X10% 36 74%
HER-2 status
Positive 29 79% 0.014
Negative 36 50%
Age above and below 50 years was used to separate pre- and postmenopausal
patients crudely. Oestrogen receptor positivity was a tumour with X5% nuclei
expressing the ER receptor for both DCIS and IBC. A comparison of COX-2
positivity with Ki67 cell proliferation above and below 10% was used because the
median DCIS cell proliferation was approximately 10%. HER-2 positivity was an
immunostaining score of X2+ (reference laboratory standard). Categorical variables
were compared differences using the w
2 test. COX-2¼cyclooxygenase type-2;
DCIS¼ductal carcinoma in situ;I B C ¼invasive breast cancer; ER¼oestrogen
receptor.
aw
2 test.
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positivity) DCIS lesions compared to low-grade DCIS lesions
(44% positivity, Table 2, Figure 2). Similarly, there was a positive
association of COX-2 immunoreactivity with cell proliferation in
DCIS (P¼0.004, Kruskal–Wallis test, Figure 2). The group of
DCIS tumours with a ki67 cell proliferation of X10% (n¼90) was
associated with 79% COX-2 positivity compared to 55% in the
group with o10% (n¼93) of cell expressing the Ki67 antigen
(Po0.0001, w
2 test, Table 2). There was a significant association
between ER negativity (40% of DCIS) and COX-2 positivity, with
80% of ER-negative DCIS showing COX-2 positivity compared to
58% of ER-positive DCIS tumours (P¼0.003, w
2 test, Table 2). The
overall HER-2 positivity rate for DCIS tumours selected for this
series was 55%. Cyclooxygenase type-2 positivity was significantly
higher in HER-2-positive DCIS tumours (82%) than HER-2-
negative tumours (48%, Po0.0001, Table 2, Figure 3).
COX-2 expression in IBC and other clinco-pathological
parameters
There was no significant association between COX-2 expression in
IBC with patient age or with nuclear grade, although the
percentage of COX-2 positivity was greater in high-grade
compared to non-high-grade tumours (Table 2, Figure 2). Similar
to DCIS, there was an association between COX-2 expression in
IBC with a higher cell proliferation (Ki67, P¼0.04, w
2 test), HER-2
positivity (P¼0.014) and with ER negativity (P¼0.005).
COX-2 expression and cell proliferation in normal breast
Although the median cell proliferation was lower in normal breast
compared to in situ and invasive cancer, there was a significant
association between increasing cell proliferation and COX-2
expression in normal breast ductal epithelium in both reduction
mammoplasty tissue (P¼0.03, Mann–Whitney test) and from
around DCIS (P¼0.004, Figure 2).
DISCUSSION
Cyclooxygenase type-2 is overexpressed along the continuum of
carcinogenesis from preinvasive lesions to metastatic disease in
tissues of both squamous and glandular origin (Eberhart et al,
1994; Kirschenbaum et al, 2000; Shirahama, 2000; Soslow et al,
2000; Morris et al, 2001; Costa et al, 2002). Cyclooxygenase type-2
overexpression in IBCs is associated with unfavourable prognostic
indices (Ristimaki et al, 2002; Denkert et al, 2003; Spizzo et al,
2003). Evidence from both human and animal studies strongly
suggests that cancer can be prevented by COX-2 inhibition.
This is the largest study to demonstrate elevated COX-2
expression in pure DCIS and has shown COX-2 overexpression
in both in situ and IBC compared with normal breast. Since most
IBC is believed to originate from DCIS (the two coexist in about
50% of cases), the inhibition of COX-2 represents a potential target
for preventing breast cancer oncogenesis and as an adjuvant
treatment following surgery to reduce local recurrence.
In this study, COX-2 expression was determined using
immunohistochemistry on archival samples of breast tissue using
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Figure 2 Association between COX-2 expression score and cell
proliferation (Ki67-labelling index) for DCIS, IBC and normal breast. For
DCIS and IBC, individual ki67 scores are separated by nuclear grade. The
thick black horizontal lines represent the median Ki67 score for each COX-
2 score (0–3) for each tissue. For each tissue type, there is a significant
increase in Ki67 with increasing COX-2 score. In DCIS and IBC, the median
Ki67 increases with increasing nuclear grade, although this is only significant
for DCIS (P¼0.003).
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yscoring systems reported by others (Half et al, 2002; Ristimaki et al,
2002). Overall, COX-2 overexpression was demonstrated in 67% of
DCIS and 63% of invasive tumours. For DCIS, this is consistent
with the studies that have reported COX-2 in DCIS tumours
(Soslow et al, 2000; Half et al, 2002; Shim et al, 2003; Watanabe
et al, 2003).
The few published data with regard to COX-2 expression in
normal breast tissue are conflicting. Using RT-PCR, Half et al
(2002) reported a lower COX-2 mRNA level in normal breast tissue
than in paired neoplastic tissue in eight of nine samples, while
Watanabe et al (2003) found no COX-2 mRNA in normal breast
tissue examined. Costa et al (2002) reported COX-2 protein
expression in eight of 46 IBCs using Western immunoblotting, but
found no COX-2 antigen in the adjacent normal tissue samples
studied. This discrepancy can be partly explained by the paucity of
ductal units in ‘normal breast’ (mostly stromal tissue in which
COX-2 is not expressed) in comparison to neoplastic tissue.
By immunohistochemistry, COX-2 expression has been reported
in normal breast ductules surrounding non-low-grade DCIS at
levels equal (15%) or higher (85%) than in the index neoplastic
lesion (Shim et al, 2003), although immuno-positivity decreases
with distance. A similar finding was reported by Half and
colleagues with expression in 81% of 48 samples, although they
found staining to be focal and generally similar or decreased in
intensity relative to adjacent neoplastic epithelia (Half et al, 2002).
Watanabe et al (2003) reported a low level of COX-2 expression in
50% of normal epithelia surrounding DCIS, but in only 15% of
normal epithelia surrounding invasive disease. This is confirms the
findings of Soslow et al (2000), who reported expression in only
three out of (17%) of normal breast tissue close to invasive cancer.
We demonstrated COX-2 immunoreactivity in 45% of normal
breast adjacent to DCIS, consistent with the findings of Wanatabe
et al, but we only scored this as COX-2 positive in 22% of cases.
However, the normal ductules examined in the present study were
on tissue sections taken from blocks of normal tissue harvested
macroscopically close to the neoplastic tissue (not necessarily on
ducts directly adjacent to the neoplastic lesion), which in reality
may be up to 2cm distal to the margin of the index neoplastic
lesion. This may explain why our COX-2 positivity in adjacent
normal breast is lower than that reported by others. We did not
report expression in normal ducts surrounding invasive cancer.
The present study is the first to report COX-2 expression in normal
breast from reduction mammoplasty tissue. We found immunor-
eactivity in 58% of samples, but only scored this as COX-2 positive
in 23%, which is not statistically different from the expression in
normal ducts surrounding DCIS (P¼0.29).
The COX-2 positivity (63%) rate in IBCs in this study is higher
than in other studies (Soslow et al, 2000; Half et al, 2002; Ristimaki
et al, 2002; Spizzo et al, 2003; Watanabe et al, 2003), which have
reported expression in 36-56% of tumours. This disparity can be
explained by the deliberate selection of HER-2-positive invasive
tumours in this study (45%), chosen to compare COX-2 expression
between HER-2-expressing and non-HER-2-expressing cancers.
HER-2 is overexpressed in approximately 20-30% of IBCs (and
therefore lower overall than in this study), and is an independent
marker of poor prognostic disease (Tsutsui et al, 2002). An
association between HER-2 and COX-2 expression in IBC has been
reported in cell line (Vadlamudi et al, 1999; Subbaramaiah et al,
2002b), animal (Howe et al, 2002) and in human immunohisto-
chemical studies (Ristimaki et al, 2002). Ristimaki et al (2002)
found a higher COX-2 expression in HER-2-expressing breast
cancer; the present study confirmed this association. Furthermore,
dual drug blockade of COX-2 and HER-2 in cancer cell lines
expressing both oncogenes has been shown to reduce cell growth
more effectively than the inhibition by one of the agents alone
(Mann et al, 2001). These studies suggest that signalling through
the HER-2 receptor may have a role in modulating the
upregulation of COX-2 in IBC.
Figure 3 (A) DCIS showing minimal COX-2 expression with scanty
brown cytoplasmic immunostaining (score 1þ, classified as COX-2
negative), (B) moderate COX-2 staining with approximately 5060% of
cells strongly stained (score 2þ, classified as COX-2 positive), (C) High
COX-2 expression in cribriform DCIS with 100% of cells intensely stained
(score 3þ, classified as COX-2 positive), (D) HER-2 staining in DCIS: note
the strong membranous staining (score 3þ, classified HER-2 positive).
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DCIS tumours and is associated with high-grade phenotype
(Allred et al, 1993; Bobrow et al, 1995; Suo et al, 2001), we
investigated the association of COX-2 and HER-2 expression in
DCIS. The overall HER-2 positivity rate for DCIS in this study
was only 55%, reflecting the deliberate inclusion of a higher
proportion of non-high-grade DCIS tumours in this study
(associated with a lower HER-2 positivity) to investigate COX-2
expression across nuclear grades. Consistent with the findings
in invasive tumours, we found that COX-2 positivity was
significantly higher in HER-2-positive DCIS (82%) than in
HER-2-negative DCIS (48%). Importantly, this finding in in situ
breast cancer confirms the association of the HER-2 receptor
with COX-2 overexpression reported in breast cancer cell line
studies (Vadlamudi et al, 1999; Subbaramaiah et al, 2002a)
(and by immunohistochemistry; Ristimaki et al, 2002), which
suggest that signalling through HER-2/Ras/Map kinase pathway
may play a role in upregulating COX-2 in neoplasia and this
may occur at the preinvasive stage of breast cancer carcino-
genesis. This could explain why COX-2 expression is higher in
DCIS than IBC.
Inhibition of the COX-2 enzyme and attenuation of the
consequential carcinogenic effects of overexpression with in-
creased prostaglandin production (inhibition of apoptosis, stimu-
lation of neo-angiogenesis, upregulation of intra-tumoral CYP19
aromatase; Davies et al, 2002) at this stage has the potential to
prevent progression to invasion.
In DCIS tumours, we also found COX-2 expression to be
positively associated with higher cellular proliferation rates, higher
nuclear grade and with ER negativity. These findings, together with
the association of COX-2 with HER-2 expression, are consistent
with those reported in IBC (Ristimaki et al, 2002). This is
important since these factors are surrogate markers of an
aggressive DCIS phenotype and link nonoestrogen growth factor
signalling pathways with COX-2 overexpression. The association of
COX-2 expression with nuclear grade in DCIS confirms the
findings of Shim et al (2003). Since nuclear grade is an
independent marker of DCIS local recurrence (Silverstein et al,
1996; Boland et al, 2003a), further study is warranted to determine
whether COX-2 is independent of grade with regard to the risk
local DCIS recurrence following breast conservation.
These findings may have important therapeutic and cancer
chemo-preventative implications. Since signalling through HER-2
pathways is believed to be involved in driving cell proliferation in
ER-negative IBC and to resist anti-oestrogen therapy in ER-
expressing/HER-2-positive cancers, the association of COX-2 with
HER-2 expression in DCIS suggests that the carcinogenic sequalae
of COX-2 overexpression originate at the preinvasive stage in
breast carcinogenesis.
There is a clinical need to determine whether women with HER-
2-positive/COX-2-positive DCIS represent a high-risk patient
population for disease progression or local recurrence; this cohort
especially may benefit form COX-2 inhibitor therapy. Phase II
clinical trials are presently in progress to determine the efficacy of
COX-2 inhibition combined with Herceptin in HER-expressing
metastatic breast cancer.
The targeting of nonhormonal pathways will be necessary to
prevent both ER-positive and ER-negative breast cancer. Since
COX-2 inhibition is a relatively safe therapeutic option, we believe
that prospective clinical trials are warranted to determine the
clinical benefit of long-term COX-2 inhibition in preventing breast
cancer and as an adjuvant therapy after DCIS treatment.
REFERENCES
Allred DC, O’Connell P, Fuqua SA (1993) Biomarkers in early breast
neoplasia. J Cell Biochem 17G(Suppl): 125–131
Alshafie GA, Abou-Issa HM, Seibert K, Harris RE (2000) Chemotherapeutic
evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary
tumor model. Oncol Rep 7: 1377–1381
Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H,
Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R
(2001) Evaluation of the United States Food and Drug Administration –
approved scoring and test system of HER-2 protein expression in breast
cancer. Clin Cancer Res 7: 1669–1675
Bobrow LG, Happerfield LC, Gregory WM, Millis RR (1995) Ductal
carcinoma in situ: assessment of necrosis and nuclear morphology and
their association with biological markers. J Pathol 176: 333–341
Boland GP, Chan KC, Knox WF, Roberts SA, Bundred NJ (2003a) Value of
the Van Nuys Prognostic Index in prediction of recurrence of ductal
carcinoma in situ after breast-conserving surgery. Br J Surg 90: 426–432
Boland GP, Mckeown A, Chan KC, Prasad R, Knox WF, Bundred NJ
(2003b) Biological response to hormonal manipulation in oestrogen
receptor positive ductal carcinoma in situ of the breast. Br J Cancer 89:
227–283
Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A,
Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E (2001) Up-regulation of
cyclooxygenase 2 gene expression correlates with tumor angiogenesis in
human colorectal cancer. Gastroenterology 121: 1339–1347
Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC (2002)
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph
node metastasis in human breast cancer. J Clin Pathol 55: 429–434
Davies G, Martin LA, Sacks N, Dowsett M (2002) Cyclooxygenase-2 (COX-
2), aromatase and breast cancer: a possible role for COX-2 inhibitors in
breast cancer chemoprevention. Ann Oncol 13: 669–678
Denkert C, Winzer K-J, Muller B-M, Weichert W, Pest S, Kobel M,
Kristiansen G, Reles A, Siegert A, Guski H, Hauptmann S (2003) Elevated
expression of cyclooxygenase-2 is a negative prognostic factor for disease
survival and overall survival in patients with breast cancer. Cancer 97:
2978–2987
Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen
FJ, Veronesi P, O’Brien ME, Scott T, Muchmore DB (2001) Effect of
raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind,
placebo-controlled, randomized clinical trial in postmenopausal patients.
Cancer Epidemiol Biomarkers Prev 10: 961–966
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois
RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human
colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183–
1188
Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ (1998) Evidence
of significant apoptosis in poorly differentiated ductal carcinoma in situ
of the breast. Br J Cancer 78: 788–794
Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ (2000) Effects of a
pure antiestrogen on apoptosis and proliferation within human breast
ductal carcinoma in situ. Cancer Res 60: 4284–4288
Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002)
Cyclooxygenase-2 expression in human breast cancers and adjacent
ductal carcinoma in situ. Cancer Res 62: 1676–1681
Harris RE, Alshafie GA, Abou-Issa H, Seibert K (2000) Chemoprevention of
breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer
Res 60: 2101–2103
Hasturk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS (2002)
Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial
epithelium and nonsmall cell lung carcinoma. Cancer 94: 1023–1031
Holland PA, Knox WF, Potten CS, Howell A, Anderson E, Baildam AD,
Bundred NJ (1997) Assessment of hormone dependence of comedo
ductal carcinoma in situ of the breast. J Natl Cancer Inst 89: 1059–1065
Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler
HT, Muller WJ, Du B, Brown AM, Dannenberg AJ (2002) Celecoxib, a
selective cyclooxygenase 2 inhibitor, protects against human epidermal
growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res
62: 5405–5407
Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cycloox-
ygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer
Inst 90: 455–460
COX-2 expression in DCIS
GP Boland et al
428
British Journal of Cancer (2004) 90(2), 423–429 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yKhuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis.
Br J Cancer 84: 1188–1192
Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, Levine AC
(2000) Expression of cyclooxygenase-1 and cyclooxygenase-2 in the
human prostate. Urology 56: 671–676
Komhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, Koch MO,
Shappell SB, Breyer MD (2000) Enhanced expression of cyclooxygenase-2
in high grade human transitional cell bladder carcinomas. Am J Pathol
157: 29–35
Kundu N, Fulton AM (2002) Selective cyclooxygenase (COX)-1 or COX-2
inhibitors control metastatic disease in a murine model of breast cancer.
Cancer Res 62: 2343–2346
Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C,
Lane TF, Hla T (2001) Overexpression of cyclooxygenase-2 is sufficient
to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563–
18569
Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX,
DuBois RN (2001) Targeting cyclooxygenase 2 and HER-2/neu
pathways inhibits colorectal carcinoma growth. Gastroenterology 120:
1713–1719
Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer
JL, Woerner BM, Snyder PW, Koki AT (1999) Expression of
cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma
(TCC) of the urinary bladder. Cancer Res 59: 5647–5650
Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE (2001)
Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-
adenocarcinoma sequence. Am J Gastroenterol 96: 990–996
Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenber-
ger G (2002) Transgenic cylclooxygenase-2 overexpression sensitizes
mouse skin for carcinogenesis. Proc Natl Acad Sci USA 99: 12483–12488
Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM
(1997) Cyclooxygenase-2 expression in human breast cancer. Int J Oncol
10: 503–507
Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S,
Haglund C (2001) Expression of cyclooxygenase-2 in human transitional
cell carcinoma of the urinary bladder. Am J Pathol 158: 849–853
Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C,
Joensuu H, Isola J (2002) Prognostic significance of elevated cycloox-
ygenase-2 expression in breast cancer. Cancer Res 62: 632–635
Rozic JG, Chakraborty C, Lala PK (2001) Cyclooxygenase inhibitors retard
murine mammary tumor progression by reducing tumor cell migration,
invasiveness and angiogenesis. Int J Cancer 93: 497–506
Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP,
Jabbour HN (2001) Cyclooxygenase-2 expression and prostaglandin E(2)
synthesis are up- regulated in carcinomas of the cervix: a possible
autocrine/paracrine regulation of neoplastic cell function via EP2/EP4
receptors. J Clin Endocrinol Metab 86: 2243–2249
Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura
S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and -2
in human colorectal cancer. Cancer Res 55: 3785–3789
Shaheen NJ, Straus WL, Sandler RS (2002) Chemoprevention of gastro-
intestinal malignancies with nonsteroidal antiinflammatory drugs.
Cancer 94: 950–963
Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, Yano M,
Inoue M, Matsuura N, Shiozaki H, Monden M (2000) Up-regulation of
cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin
Cancer Res 6: 1229–1238
Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I,
Tlsty TD, Esserman LJ (2003) Cyclooxygenase-2 expression is related to
nuclear grade in ductal carcinoma in situ and is increased in its normal
adjacent epithelium. Cancer Res 63: 2347–2350
Shirahama T (2000) Cyclooxygenase-2 expression is up-regulated in
transitional cell carcinoma and its preneoplastic lesions in the human
urinary bladder. Clin Cancer Res 6: 2424–2430
Shirahama T, Arima J, Akiba S, Sakakura C (2001) Relation between
cyclooxygenase-2 expression and tumor invasiveness and patient
survival in transitional cell carcinoma of the urinary bladder. Cancer
92: 188–193
Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn
WJ, Poller DN (1996) A prognostic index for ductal carcinoma in situ of
the breast. Cancer 77: 2267–2274
Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J,
Koki AT (2000) COX-2 is expressed in human pulmonary, colonic, and
mammary tumors. Cancer 89: 2637–2645
Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A,
Margreiter R, Obrist P (2003) Correlation of COX-2 and Ep-CAM
overexpression in human invasive breast cancer and its impact on
survival. Br J Cancer 88: 574–578
Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ (2002a) Cycloox-
ygenase-2 is overexpressed in HER-2/neu-positive breast cancer:
evidence for involvement of AP-1 and PEA3. J Biol Chem 277: 18649–
18657
Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ (2002b) Cycloox-
ygenase-2 is overexpressed in HER-2/neu-positive breast cancer:
evidence for involvement of AP-1 and PEA3. J Biol Chem 277: 18649–
18657
Suo Z, Bjaamer A, Ottestad L, Nesland JM (2001) Expression of EGFR
family and steroid hormone receptors in ductal carcinoma in situ of the
breast. Ultrastruct Pathol 25: 349–356
Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis
in epithelial cells overexpressing prostaglandin endoperoxide synthase 2.
Cell 83: 493–501
Tsujii M, Kawano S, DuBois RN (1997) Cyclooxygenase-2 expression in
human colon cancer cells increases metastatic potential. Proc Natl Acad
Sci USA 94: 3336–3340
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998)
Cyclooxygenase regulates angiogenesis induced by colon cancer cells.
Cell 93: 705–716
Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S (2002) Prognostic
value of c-erbB2 expression in breast cancer. J Surg Oncol 79: 216–223
Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow
RA, Masferrer JL, Woerner BM, Koki AT, Fahey III TJ (1999)
Cyclooxygenase-2 expression is up-regulated in human pancreatic
cancer. Cancer Res 59: 987–990
Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R
(1999) Regulation of cyclooxygenase-2 pathway by HER2 receptor.
Oncogene 18: 305–314
Watanabe O, Shimizu T, Kinoshita J, Utada Y, Okabe T, Kimura K, Hirano
A, Yoshimatsu K, Aiba M, Ogawa K (2003) Expression of cyclooxygen-
ase-2 in malignant and benign breast tumours. Anticancer Res 23: 3215–
3221
Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A
(1998) Expression of cyclooxygenase-2 in human lung carcinoma. Cancer
Res 58: 4997–5001
COX-2 expression in DCIS
GP Boland et al
429
British Journal of Cancer (2004) 90(2), 423–429 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y